NCT04802902Completed
Feasibility of Immunotherapy Plus Chemotherapy Administration to Patients With Bronchial Cancer in a Hospital-at- Home Setting
Feasibility of Immunotherapy Plus Chemotherapy Administration to Patients With Bronchial Cancer in a Hospital-at- Home Setting - CombHADom
Source: ClinicalTrials.gov · Last updated 26 Feb 2024
Brief summary (registry, in English)
This observational prospective monosite study aims to describe, for the first time, management in a hospital-at-home programme of patients treated by immunotherapy-chemotherapy combo for bronchial cancer in maintenance phase of first row metastatic treatment. The feasibility in good conditions of this management, the patients' quality of life and their satisfaction will be evaluated. A cost-benefit analysis will be done to compare hospital-at-home programme and classical day hospitalization.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 10 (actual)
- First submitted
- 15 Mar 2021
- Start date
- 29 Sept 2021
- Primary completion date
- 8 Feb 2024
- Lead sponsor
- Centre Hospitalier de PAU
- NCT number
- NCT04802902
What you commit to
- Study type: Observational
- Participants enrolled: 10
- From 29 Sept 2021 to the primary completion date, 8 Feb 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Frail patients requiring a frequent medical assessment thus day hospitalization cares
Who the study is looking for
- Patients aged 18 and over,
- with bronchial metastatic cancer treated in first row maintenance phase by immunotherapy-chemotherapy combo,
- having at least one assessments of the response to immunotherapy received in day hospitalization with efficiency (stability or partial response),
- without any graded higher than 1 adverse effects, or uncontrolled grade 1 adverse effects related to immunotherapy
- eligible for a home-based hospitalization
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Hospitalier de Pau Coordinator of this site? Confirm its status | Pau | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.